These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 15293524

  • 1. Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site.
    Uttley L, Vardhan A, Mahajan S, Smart B, Hutchison A, Gokal R.
    J Nephrol; 2004; 17(2):242-5. PubMed ID: 15293524
    [Abstract] [Full Text] [Related]

  • 2. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis.
    Thodis E, Passadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemezis V.
    Adv Perit Dial; 2000; 16():257-61. PubMed ID: 11045306
    [Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients.
    Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L, Piraino B.
    J Am Soc Nephrol; 2005 Feb; 16(2):539-45. PubMed ID: 15625071
    [Abstract] [Full Text] [Related]

  • 4. Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience.
    Cavdar C, Saglam F, Sifil A, Celik A, Atay T, Gungor O, Ozder A, Gulay Z, Camsari T.
    Ren Fail; 2008 Feb; 30(4):417-22. PubMed ID: 18569916
    [Abstract] [Full Text] [Related]

  • 5. The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital.
    Lim CT, Wong KS, Foo MW.
    Nephrol Dial Transplant; 2005 Aug; 20(8):1702-6. PubMed ID: 15855200
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis.
    Xu G, Tu W, Xu C.
    Nephrol Dial Transplant; 2010 Feb; 25(2):587-92. PubMed ID: 19679557
    [Abstract] [Full Text] [Related]

  • 8. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years.
    Lobbedez T, Gardam M, Dedier H, Burdzy D, Chu M, Izatt S, Bargman JM, Jassal SV, Vas S, Brunton J, Oreopoulos DG.
    Nephrol Dial Transplant; 2004 Dec; 19(12):3140-3. PubMed ID: 15466881
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of gentamicin and mupirocin in the prevention of exit-site infection and peritonitis in peritoneal dialysis.
    Mahaldar A, Weisz M, Kathuria P.
    Adv Perit Dial; 2009 Dec; 25():56-9. PubMed ID: 19886318
    [Abstract] [Full Text] [Related]

  • 11. Outcome and clinical implications of a surveillance and treatment program for Staphylococcus aureus nasal carriage in peritoneal dialysis patients.
    Crabtree JH, Hadnott LL, Burchette RJ, Siddiqi RA.
    Adv Perit Dial; 2000 Dec; 16():271-5. PubMed ID: 11045309
    [Abstract] [Full Text] [Related]

  • 12. Effect of local mupirocin application on exit-site infection and peritonitis in an Indian peritoneal dialysis population.
    Mahajan S, Tiwari SC, Kalra V, Bhowmik DM, Agarwal SK, Dash SC, Kumar P.
    Perit Dial Int; 2005 Dec; 25(5):473-7. PubMed ID: 16178481
    [Abstract] [Full Text] [Related]

  • 13. The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital.
    Lim CT, Wong KS, Foo MW.
    Nephrol Dial Transplant; 2005 Oct; 20(10):2202-6. PubMed ID: 16046516
    [Abstract] [Full Text] [Related]

  • 14. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.
    Thodis E, Bhaskaran S, Pasadakis P, Bargman JM, Vas SI, Oreopoulos DG.
    Perit Dial Int; 1998 Oct; 18(3):261-70. PubMed ID: 9663889
    [Abstract] [Full Text] [Related]

  • 15. Mupirocin application at the exit site in peritoneal dialysis patients: five years of experience.
    Aykut S, Caner C, Ozkan G, Ali C, Tugba A, Zeynep G, Taner C.
    Ren Fail; 2010 Jan; 32(3):356-61. PubMed ID: 20370452
    [Abstract] [Full Text] [Related]

  • 16. Prevention of staphylococcal peritonitis in CAPD patients combining ablution and mupirocin.
    Al-Hwiesh AK, Abdul Rahman IS.
    Saudi J Kidney Dis Transpl; 2008 Sep; 19(5):737-45. PubMed ID: 18711288
    [Abstract] [Full Text] [Related]

  • 17. Prevention of peritoneal dialysis catheter infections in Saudi peritoneal dialysis patients: the emergence of high-level mupirocin resistance.
    Al-Hwiesh AK, Abdul-Rahman IS, Al-Muhanna FA, Al-Sulaiman MH, Al-Jondebi MS, Divino-Filho JC.
    Int J Artif Organs; 2013 Jul; 36(7):473-83. PubMed ID: 23897229
    [Abstract] [Full Text] [Related]

  • 18. [Prophylaxis and management of catheter-associated infections in peritoneal dialysis patients: recent studies and guidelines].
    Kopriva-Altfahrt G, Moser E, Prokschi A, Kraus B, Kovarik J.
    Wien Klin Wochenschr; 2005 Jul; 117 Suppl 6():73-82. PubMed ID: 16437337
    [Abstract] [Full Text] [Related]

  • 19. Lack of correlation between nasal cultures positive for Staphylococcus aureus and the development of S. aureus exit-site infections: results unaffected by routine mupirocin treatment of nasal S. aureus carriage.
    Hanslik TM, Newman L, Tessman M, Morrissey AB, Friedlander MA.
    Adv Perit Dial; 1994 Jul; 10():158-62. PubMed ID: 7999817
    [Abstract] [Full Text] [Related]

  • 20. An integrated critique of the efficacy of topical mupirocin in preventing catheter-related Staphylococcus aureus infections in peritoneal dialysis clients.
    Pratt O.
    CANNT J; 2002 Jul; 12(1):20-8. PubMed ID: 11979650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.